John Foster, MD
Obstetrics & Gynecology · Birmingham, ALNPI 1376563429
Payments from drug & device makers
Across 223 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$461
- Pfizer$401
- AbbVie$387
- Myriad Women's Health, Inc.$323
- Amgen$308
- Astellas Pharma US Inc$261
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,16499%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 21 | $461 |
| Pfizer | 25 | $401 |
| AbbVie | 22 | $387 |
| Myriad Women's Health, Inc. | 2 | $323 |
| Amgen | 18 | $308 |
| Astellas Pharma US Inc | 18 | $261 |
| Medtronic | 4 | $198 |
| Urovant Sciences Inc | 11 | $185 |
| Mayne Pharma Commercial LLC | 12 | $164 |
| Bayer | 8 | $139 |
| Therapeuticsmd, Inc. | 8 | $109 |
| Hologic Sales And Service, LLC | 7 | $106 |
| Millicent US Inc | 5 | $96 |
| Avion Pharmaceuticals | 5 | $90 |
| Aspira Women's Health Inc | 1 | $83 |
| Evofem Biosciences, Inc. | 5 | $82 |
| Boston Scientific | 4 | $74 |
| Mission Pharmacal Company | 5 | $73 |
| Coopersurgical, Inc. | 4 | $68 |
| Exeltis, USA Inc. | 4 | $64 |
| Organon | 3 | $61 |
| Mylan Pharmaceuticals Inc. | 4 | $60 |
| Myovant Sciences Inc. | 4 | $52 |
| Radius Health, Inc. | 3 | $45 |
| Vertical Pharmaceuticals, LLC | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Shield Therapeutics Inc | 2 | $41 |
| Intuitive Surgical | 1 | $26 |
| AMAG Pharmaceuticals, Inc. | 2 | $26 |
| Minerva Surgical, Inc | 1 | $22 |
| Roche Diagnostics Corporation | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Axonics, Inc. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Merck | 1 | $14 |
| Duchesnay USA Incorporated | 1 | $13 |
| Convatec Inc. | 1 | $12 |
| Coloplast | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,216 in reported general payments places this provider in the 80th percentile of 537 obstetrics & gynecology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 69 | $46,166 |
| MyrbetriqMirabegron | 53 | $31,619 |
| ProliaDenosumab | 14 | $23,907 |
| PremarinEstrogens, Conjugated | 36 | $15,377 |
| Estradiol | 384 | $13,694 |
| Risedronate Sodium | 45 | $10,454 |
| Trospium Chloride ErTrospium Chloride | 33 | $7,153 |
| VeozahFezolinetant | 11 | $6,522 |
| PremproEstrogen,con/M-Progest Acet | 17 | $5,781 |
| Estradiol (Twice Weekly)Estradiol | 28 | $3,546 |
| CombipatchEstradiol/Norethindrone Acet | 13 | $3,056 |
| ProgesteroneProgesterone, Micronized | 52 | $2,795 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $2,291 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 13 | $2,181 |
| Clobetasol Propionate | 23 | $1,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $461 | $46,16669 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $261 | $38,14164 claims |
| AmgenProlia | $308 | $23,90714 claims |
| PfizerPremarin, Prempro | $401 | $21,15853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 537 obstetrics & gynecology providers in Alabama.
Other obstetrics & gynecology in Birmingham
- Charles SharpBirmingham$2.8M
- Ronald OrsoBirmingham$1.6M
- Theodore TsaltasBirmingham$853K
- Janeen ArbuckleBirmingham$601K
- Tomeka RobertsBirmingham$44K
- Percy HudsonBirmingham$29K
- Heidi StraughnBirmingham$29K
- William HudsonBirmingham$13K
- William JohnsonBirmingham$10K
- Cynthia BrownBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.